Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK

The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical

      BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions

      Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.

        Mark Vickery headshot

        Top Analyst Reports for Johnson & Johnson, Nike & Schlumberger

        Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Nike (NKE) and Schlumberger (SLB).

          Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

          J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

            Swarup Gupta headshot

            Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress

            The index posted impressive gains this week, boosted by a strong economy and expectations of robust earnings.

              Brian Hamilton headshot

              Johnson & Johnson and General Motors: Growth and Income Stocks

              This week I discuss two companies within the Income Investor portfolio; Johnson & Johnson (JNJ) and General Motors (GM).

                Interpublic's Weber Shandwick Acquires Social Agency That Lot

                Interpublic's (IPG) Weber Shandwick acquires That Lot to boost its multi-platform capabilities and expand client base globally.

                  J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

                  The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

                    Sweta Killa headshot

                    Healthcare ETFs in Focus Following JNJ Q2 Results

                    Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.

                      Stock Market News For Jul 18, 2018

                      Markets closed sharply higher on Tuesday, led by a rally in tech stocks.

                        J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

                        A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                          Ryan McQueeney headshot

                          Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch

                          Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.

                            J&J's (JNJ) Phase III Study for Invokana Halted Earlier

                            Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.

                              Tracey Ryniec headshot

                              These Companies are Earnings All-Stars

                              It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?

                                J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales

                                J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.

                                  Watch Out For Goldman

                                  Watch Out For Goldman

                                    Stock Market News For July 17, 2018

                                    Financial stocks jumped on Monday although the broader market struggled, as impressive economic data and quarterly results failed to boost investors??? confidence.

                                      Mark Vickery headshot

                                      Goldman Beats in Blankfein's Final Quarter

                                      Goldman Sachs (GS) CEO and Chairman Lloyd Blankfein announced his replacement this morning as the company he's run for the past 12 years easily beat earnings and revenue projections in its Q2 report.

                                        J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

                                        A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

                                          J&J (JNJ) Down on Trimmed View Despite Q2 Earnings Beat

                                          J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it tightens its previously issued earnings guidance for 2018 while lowering its sales range.

                                            Pacira Focused on Exparel Development Amid Competition

                                            Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

                                              Afrasiab Mian headshot

                                              Johnson & Johnson (JNJ) Slips 1.1% Ahead of Earnings: What To Watch

                                              Shares of Johnson & Johnson (JNJ) ticked down 1.1% during regular hours Monday, the last day of trading before it releases its latest quarterly earnings report. Investors displayed hesitation ahead of the report, but this is certainly still a stock to watch once the full results are in.

                                                J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

                                                The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

                                                  Company News For Jul 16, 2018

                                                  Companies in the news are: JNJ, T, AAPL and CSCO